Holen Sie sich die Stockscreener-App
196.11
5.35%
-11.08
Vorhandelsmarkt:
196.63
0.52
+0.27%
Schlusskurs vom Vortag:
$207.19
Offen:
$205.01
24-Stunden-Volumen:
1.85M
Relative Volume:
1.52
Marktkapitalisierung:
$27.79B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$-208.16M
KGV:
-127.63
EPS:
-1.5366
Netto-Cashflow:
$76.11M
1W Leistung:
-3.39%
1M Leistung:
-0.79%
6M Leistung:
+8.62%
1J Leistung:
+30.59%
1-Tages-Spanne:
$194.29
$205.66
1-Wochen-Bereich:
$184.00
$219.47
52-Wochen-Spanne:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Firmenname
Natera Inc
Sektor
Branche
Telefon
650-249-9090
Adresse
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
196.11 | 29.37B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
516.00 | 197.58B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
193.78 | 140.22B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.95 | 46.13B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
118.25 | 33.85B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
319.04 | 32.02B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | Citigroup | Buy |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-10-27 | Hochstufung | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-08 | Fortgesetzt | Craig Hallum | Buy |
| 2024-02-20 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-11-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Eingeleitet | Stephens | Overweight |
| 2022-03-08 | Eingeleitet | Goldman | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-09-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-09-17 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-05-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Eingeleitet | JP Morgan | Neutral |
| 2018-07-05 | Bestätigt | Piper Jaffray | Overweight |
| 2017-08-07 | Bestätigt | Morgan Stanley | Overweight |
| 2016-11-10 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-05-11 | Bestätigt | The Benchmark Company | Buy |
| 2016-04-19 | Eingeleitet | The Benchmark Company | Buy |
| 2015-09-28 | Hochstufung | Wedbush | Neutral → Outperform |
| 2015-08-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-07-27 | Eingeleitet | Wedbush | Neutral |
Alle ansehen
Natera Inc Aktie (NTRA) Neueste Nachrichten
Judge hands Natera 30% ongoing royalty in MRD patent battle - MSN
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Natera positioned to capture growing $20 billion MRD opportunity: analyst - MSN
Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance? - simplywall.st
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
NTRA Initiated Coverage On by William Blair -- Rating Outperform - GuruFocus
NATERA INC : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING - Moomoo
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth? - AD HOC NEWS
William Blair initiates coverage of Natera (NTRA) with outperform recommendation - MSN
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - BioSpace
William Blair initiates Natera stock with Outperform on growth outlook - Investing.com
William Blair initiates Natera stock with Outperform on growth outlook By Investing.com - Investing.com India
Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion - TipRanks
Lymphoma patients on Allogene therapy saw ctDNA drop 97.7% by Day 45 - Stock Titan
Moving Averages: Will Natera Inc benefit from sector rotation2026 Price Momentum & Daily Stock Trend Watchlist - baoquankhu1.vn
Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller - MSN
Court orders 30% ongoing royalty for Natera in patent dispute - MSN
Aug Closing: Can Natera Inc outperform in the next rallyBull Run & AI Optimized Trade Strategies - baoquankhu1.vn
Assessing Natera (NTRA) Valuation After Patent Win Product Momentum And Upcoming Cancer Data - simplywall.st
A Look At Natera (NTRA) Valuation After Legal Win And Growing Signatera Adoption - Yahoo Finance
Natera Claims Top Trading Volume as Legal Victory Sparks $550 Million Surge Amid Price Drop - Bitget
Natera (NTRA) slides 4.9% as investors digest mixed signals: analyst caution, legal overhang, and post-court-ruling repositioning - Quiver Quantitative
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Secures 30% Royalty in Patent Dispute - GuruFocus
Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing - Stock Titan
Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com - Investing.com Australia
3 Reasons NTRA Has Explosive Upside Potential - Yahoo Finance
Natera Inc (NTRA) Shares Gap Down to $201.16 on Apr 9 - GuruFocus
Natera (NTRA) Wins Increased Royalty in Delaware Court Decision - GuruFocus
Natera awarded 30% ongoing royalty in MRD patent litigation - MSN
Judge Awards 30% Ongoing Royalty to Natera for Its MRD-Related Patents - Moomoo
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle - Benzinga
Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales - marketscreener.com
Natera wins 30% ongoing royalty in patent case against Invitae - Investing.com
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents - Yahoo Finance
Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes - Stock Titan
Buy Signal: Can Natera Inc outperform in the next rallyWeekly Trend Recap & Short-Term Trading Alerts - baoquankhu1.vn
Voya Global Insights Portfolio's Natera Inc(NTRA) Holding History - GuruFocus
Natera Award Cut by $10 Million as Invitae Faces Royalty (1) - Bloomberg Law News
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform - BioSpace
Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating - GuruFocus
56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC - MarketBeat
Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300 - Moomoo
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Singapore
Judge Slashes Damages For Natera In Invitae Patent Case - Law360
Natera, Inc. (NTRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
NTRA SEC FilingsNatera Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Finanzdaten der Natera Inc-Aktie (NTRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):